UY35412A - Formulaciones de fviii recombinante - Google Patents

Formulaciones de fviii recombinante

Info

Publication number
UY35412A
UY35412A UY0001035412A UY35412A UY35412A UY 35412 A UY35412 A UY 35412A UY 0001035412 A UY0001035412 A UY 0001035412A UY 35412 A UY35412 A UY 35412A UY 35412 A UY35412 A UY 35412A
Authority
UY
Uruguay
Prior art keywords
rfviii
formulations
bdd
mutant
pegylated
Prior art date
Application number
UY0001035412A
Other languages
English (en)
Inventor
Ma Xinghang
Wang Deqian
Tsvetkova Nelly
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of UY35412A publication Critical patent/UY35412A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan formulaciones de rFVIII líquidas y liofilizadas, incluyendo formulaciones de rFVIII de longitud completa (FL-rFVIII), formulaciones de rFVIII con el dominio B eliminado (BDD-rFVIII), y formulaciones de mutante BDD-rFVIII (mutante BDD-rVIII). También se proporcionan formulaciones de rFVIII PEGilado líquidas y liofilizadas (PEG-rFVIII), incluyendo formulaciones de rFVIII de longitud completa PEGilado (PEG-FL-rFVIII), formulaciones de rFVIII con dominio B eliminado PEGilado (PEG-BDD-rFVIII), y formulaciones de mutante BDD-rFVIII PEGilado (mutante PEGBDD- rFVIII).
UY0001035412A 2013-03-15 2014-03-13 Formulaciones de fviii recombinante UY35412A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361799495P 2013-03-15 2013-03-15
US201361869191P 2013-08-23 2013-08-23

Publications (1)

Publication Number Publication Date
UY35412A true UY35412A (es) 2014-10-31

Family

ID=51580768

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035412A UY35412A (es) 2013-03-15 2014-03-13 Formulaciones de fviii recombinante

Country Status (17)

Country Link
US (1) US20160030524A1 (es)
EP (1) EP2970430A4 (es)
JP (1) JP2016518321A (es)
KR (1) KR20150132449A (es)
CN (1) CN105209487A (es)
AU (1) AU2014237111B2 (es)
BR (1) BR112015022730A2 (es)
CA (1) CA2905739A1 (es)
HK (1) HK1213273A1 (es)
MX (1) MX2015012905A (es)
PE (1) PE20160121A1 (es)
RU (1) RU2015144076A (es)
SG (2) SG11201507618YA (es)
TW (1) TW201521761A (es)
UY (1) UY35412A (es)
WO (1) WO2014150477A1 (es)
ZA (1) ZA201507684B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190064147A1 (en) * 2015-01-18 2019-02-28 Biogen Ma Inc. Formulations and screening of biological therapeutic agents
TWI777175B (zh) 2015-11-13 2022-09-11 日商武田藥品工業股份有限公司 用於ａ型血友病基因治療之編碼表現增加之重組ｆｖｉｉｉ變異體之病毒載體
TW202039546A (zh) 2019-01-16 2020-11-01 美商巴克斯歐塔公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
US20220305089A1 (en) * 2019-08-16 2022-09-29 Octapharma Ag Stabilizing buffer for factor viii and vwf

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP1152450A4 (en) * 1999-02-01 2004-04-14 Nippon Electric Glass Co CATHODE RAY TUBE AND METHOD FOR THE PRODUCTION THEREOF
BR0008405B1 (pt) * 1999-02-22 2014-04-22 Baxter Int Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa
ES2331909T3 (es) * 2001-06-14 2010-01-20 The Scripps Research Institute Factor viii estabilizado con enlaces disulfuro modificados geneticamente.
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
WO2006053299A2 (en) * 2004-11-12 2006-05-18 Bayer Healthcare Llc Site-directed modification of fviii
CA2647314A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
US20100168018A1 (en) * 2008-11-07 2010-07-01 Baxter International Inc. Factor viii formulations
EP2387413A4 (en) * 2009-01-19 2015-12-23 Bayer Healthcare Llc PROTEIN CONJUGATE WITH AN ENDOPEPTIDASE-SPLICABLE BIOPROTEKTIVES PART

Also Published As

Publication number Publication date
KR20150132449A (ko) 2015-11-25
RU2015144076A (ru) 2017-04-24
PE20160121A1 (es) 2016-03-03
EP2970430A1 (en) 2016-01-20
BR112015022730A2 (pt) 2017-10-31
AU2014237111B2 (en) 2018-06-21
SG10201803999UA (en) 2018-06-28
SG11201507618YA (en) 2015-10-29
CA2905739A1 (en) 2014-09-25
TW201521761A (zh) 2015-06-16
JP2016518321A (ja) 2016-06-23
US20160030524A1 (en) 2016-02-04
EP2970430A4 (en) 2017-01-11
CN105209487A (zh) 2015-12-30
AU2014237111A1 (en) 2015-10-08
ZA201507684B (en) 2017-06-28
HK1213273A1 (zh) 2016-06-30
MX2015012905A (es) 2016-06-16
WO2014150477A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
CO2019005966A2 (es) Esteroides y conjugados de proteínas de los mismos
CY1122101T1 (el) Τροποποιημενα πολυπεπτιδια ρελαξινης και χρησεις αυτων
MX2021012014A (es) Vectores del factor viii del virus adeno-asociado.
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CY1123622T1 (el) Τροποποιημενα μηνιγγιτιδοκοκκικα fhbp πολυπεπτιδια
MX2020014120A (es) Agonistas parciales del receptor de insulina.
UY34419A (es) Profármaco de adrenomedulina basado en polietilenglicol y el uso del mismo
MX2016001093A (es) Nanoemulsion de aminosilicona.
MX2016001094A (es) Nanoemulsion de aminosilicona.
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
UY34740A (es) Atomizador con agentes codificadores
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
UY33856A (es) ?gen y variaciones asociadas con el fenotipo bm1, marcadores moleculares y su uso?.
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso
UY35412A (es) Formulaciones de fviii recombinante
UY34783A (es) Segadora
EP3052526A4 (en) Recombinant polypeptides comprising mhc class ii 1 domains
UY4239Q (es) Silla con respaldo en forma de t
AR095431A1 (es) Formulaciones de fviii recombinante
EA201591832A1 (ru) Коэкспрессия фактора viii и фактора фон виллебранда
UA86172U (en) Suppository
UY4511U (es) Mensula telescopico-rectangular
NZ756883A (en) Adeno-associated virus factor viii vectors

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211112